Alcohol relapse prevention medication in NYC

Disulfiram is an approved alcohol-dependence treatment option that deters drinking through a potentially serious alcohol reaction. It is not a cure, an acute-withdrawal medicine or a guarantee against relapse. A suitable treatment plan includes an informed patient, alcohol-avoidance instructions, clinical monitoring and behavioral support. Another AUD medicine may better fit the patient’s goals and risks.

Disulfiram may cause drowsiness, headache or a metallic/garlic taste. More serious concerns include liver injury, nerve or visual symptoms, psychiatric changes and interactions. Alcohol exposure can trigger a severe reaction, including after stopping treatment. Contact the clinician for jaundice, dark urine, persistent nausea, numbness or vision changes; use emergency care for collapse, breathing trouble, chest pain or severe reaction symptoms.

The evaluation considers readiness for abstinence, recent alcohol use and withdrawal risk. The clinician reviews liver and heart disease, psychiatric history, pregnancy, allergies and interacting medicines. Severe myocardial disease or coronary occlusion, psychoses and certain medicines such as metronidazole or paraldehyde are important label exclusions. Being interested in a prescription is not enough if alcohol exposure or unsafe withdrawal makes the plan unsuitable.

Describe the last drink, usual drinking pattern, past withdrawal, seizures and detox treatment. The clinician determines when a start is appropriate. If significant withdrawal is likely, medical withdrawal care comes first; disulfiram cannot substitute for it.

Review what an alcohol reaction can feel like, why it can be dangerous and how long the risk lasts after stopping. Discuss medicines, foods and household products that may contain alcohol. A family member may support your plan with your agreement, but cannot administer the medicine without your knowledge.

Bring liver test results if available and ask about baseline and early follow-up monitoring. Review how the prescribed tablet will fit your day and whether agreed support would help you take it reliably. A clinician should explain missed doses; do not take extra tablets to make a deterrent stronger.

Discuss cravings, stress, sleep, mental health and drinking triggers. Counseling, recovery support or another AUD medicine may be part of the plan. If you think you may drink, contact the team before a crisis rather than testing the reaction.

The boxed warning says not to administer disulfiram during alcohol intoxication or without the patient’s full knowledge. Alcohol reactions can occur for up to fourteen days after the last tablet. Do not deliberately test drinking on it. Seek emergency care for chest pain, trouble breathing, collapse, marked confusion or severe symptoms after possible alcohol exposure. Disulfiram can also cause liver injury without a drinking reaction. Report jaundice, dark urine, loss of appetite or persistent nausea promptly. New numbness, vision problems or major mental-health changes also need review.

Tell the prescriber if you are pregnant or may become pregnant before taking disulfiram. Its suitability requires an individual benefit-risk review and alcohol/withdrawal safety assessment. Do not assume a routine AUD prescription is safe in pregnancy. Coordinate the obstetric and addiction-care plan and do not attempt a drinking reaction or abrupt unsupervised withdrawal.

Have your insurance card ready when booking. Share member details through the clinic’s confirmed secure intake process. Check with the clinic and your insurer that the exact plan covers the clinician and requested service. Ask about visit charges, any separately billed tests or medicines, and any referral or authorization requirement. Coverage and your copay or deductible depend on the plan; request a written estimate if paying yourself.

An appropriate evaluation or follow-up may be possible by video when the clinician is authorized to treat you where you are physically located. The service must confirm age, eligibility and current prescribing requirements. A video visit does not guarantee a controlled-substance prescription. Some examinations and tests need an in-person visit. Provider-administered injections require the appropriate treatment setting. Ask intake where any ordered specimens must be collected. Tell intake your actual location and requested service.

An injection does not guarantee elimination of urges. Discuss their timing, drinking, triggers and other symptoms. The clinician can review treatment fit and support without assuming that an extra or early injection is appropriate.

No. The answer depends on the diagnosis, severity, tests and the medicine. Naltrexone and disulfiram require careful liver review, while acamprosate has important kidney restrictions. Do not select or rule out a medicine from one general rule.